本季度信息
海西新药（股票代码：02637）公布截至2026年6月30日止六个月的财务数据显示，期内营收为3.12亿元，同比增长3.85%。同期净利润为0.81亿元，同比下降24.82%。研发投入达0.41亿元，占营收比重约13.08%，同比上升50.32%。本期销售与管理费用合计约1.12亿元，其中销售费用微降0.49%，管理费用增长9.41%。根据财报列示的营业收入与营业成本测算，毛利率约为81.90%，经营利润率约27.05%。
业务分项
海西新药主要业务涵盖创新药分部与仿制药分部。期内全部营收主要来源于仿制药分部，实现营收3.12亿元，同比增长3.85%。创新药分部暂无销售收入，其核心管线C019199、HX9428与HXP089在中国与美国的临床研究均取得稳步进展，其中C019199已在国内进入了骨肉瘤III期临床研究，HX9428在中美两地同步开启II期临床试验，美国FDA已授权进入II期临床并授予快速通道资格。HXP089则获准在中国开展治疗胶质母细胞瘤的临床试验。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.